Logo

Indications - • Asthma • Severe Allergic & Inflammatory Conditions • Inflammatory Skin Disease- Dermatitis • Juvenile Rheumatoid Arthritis • Rheumatoid Arthritis • Chronic Arthritis

Dosage & Administration - Inflammatory and allergic disorder: Adult: Initially 2-40 mg daily. Child: 0.5-1.7 mg/kg daily in 2-4 divided doses. Rheumatoid arthritis: Condition Initial daily dosage Condition Initial daily dosage Severe 12-16 mg Moderately severe 8-12 mg Moderate 4-8 mg Children 4-8 mg Bronchial Asthma: Up to 64 mg single dose/alternate day up to 100 mg maximum.

Side Effects - Short courses of Methylprednisolone are usually well-tolerated with few, mild side effects. Long term, high doses of Methyiprednisoione may produce predictable and potentially serious side effects. Whenever possible, the lowest effective doses of Methylprednisolone should be used for the shortest length of time to minimize side effects. Alternate day dosing also can help reduce side effects. Side effects of Methylprednisolone and other corticosteroids range from mild annoyances to serious irreversible bodily damage. Side effects include fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, hair growth on the face, glaucoma, cataracts, peptic ulceration, growth retardation in children, convulsions, and psychic disturbances including depression, euphoria, insomnia etc. Prolonged use of Methylprednisolone can depress the ability of the body's adrenal glands to produce corticosteroids. Abruptly stopping Methylprednisolone in these individuals can cause symptoms of corticosteroid insufficiency, with accompanying nausea, vomiting, and even shock. Therefore, withdrawal of Methylprednisolone usually is accomplished by gradually lowering the dose. Gradually tapering Methylprednisolone not only minimizes the symptoms of corticosteroid insufficiency, it also reduces the risk of an abrupt flare of the disease being treated.

Contraindications - Systemic fungal infections arid known hypersensitivity to components.

Others - Pregnancy & Lactation Pregnancy category C. Dregs should be given only if the potential benefit justifies the potential risk te the foetus. Mefhyiprednisofone has not been adequately evaluated in nursing mothers.